Apimeds and Lundefinedkahi Confirm FDA Meeting to Discuss LT-100
Apimeds Pharmaceuticals and Lundefinedkahi Therapeutics announced that the FDA Division of Anesthesiology, Addiction Medicine and Pain Medicine, or DAAP, has confirmed a Type C meeting to discuss LT-100 - Apitox -, a non-opioid biologic candidate being developed for the treatment of the signs and symptoms of osteoarthritis, or OA. The meeting will be conducted via teleconference on Monday, May 4. The scheduled interaction follows the recent submission of a Type C meeting request and represents an important step in the coordinated U.S. regulatory strategy for LT-100. The meeting is intended to support alignment with the FDA on key development considerations and the overall path forward for the program in the U.S. The product was originally developed and approved in South Korea, where it was approved for marketing in South Korea by the Korean Food and Drug Administration. Apimeds and Lundefinedkahi Therapeutics are now advancing the program in the U.S. by integrating its historical data with development standards.
Trade with 70% Backtested Accuracy
Analyst Views on APUS
About APUS
About the author
Inscobee Rejects Allegations from MindWave Innovations, Inc.
- Board Restructuring: On March 20, 2026, Inscobee and Apimeds Korea executed a written consent to remove four directors and appoint three new ones, effective immediately, demonstrating strong shareholder intervention and intent to restructure corporate governance.
- Executive Changes: The new board decided to remove the CEO and CFO, appointing Mr. Cho as the new CEO, aiming to drive strategic transformation and enhance operational efficiency under new leadership.
- Escalating Legal Dispute: MindWave issued a statement without authorization from the new board, alleging breaches of the support agreement by Inscobee and Apimeds Korea, potentially leading to litigation and increasing legal risks and uncertainties for the company.
- Asset Ownership Controversy: Inscobee and Apimeds Korea raised concerns over MindWave's ownership of digital assets, specifically 1000 bitcoins, indicating information asymmetry during the merger process that could affect future business integration and strategic decisions.
APIMEDS Pharmaceuticals US Inc. Names Youngjik Cho as CEO and Junyoung Yu as Secretary, Effective Immediately - SEC Filing
Leadership Changes: Young Jik Cho has been appointed as the new CEO of Pharmaceuticals, while Jun Young Yu has taken on the role of Secretary effective immediately.
Strategic Focus: The leadership transition aims to enhance the company's strategic direction and operational efficiency in the pharmaceutical sector.
APIMEDS Pharmaceuticals US Inc. Terminates Dr. Vin Menon as CEO, Effective Immediately - SEC Filing
Pharmaceutical Developments: Recent advancements in pharmaceuticals have led to significant changes in treatment protocols.
Immediate Effects: The introduction of new medications has shown immediate positive effects on patient outcomes.
Dr. Vin Menon: Dr. Vin Menon has been a key figure in these developments, contributing to the field with innovative approaches.
Regulatory Changes: The regulatory environment is adapting to accommodate these new treatments, ensuring they are safe and effective for public use.
APIMEDS PHARMACEUTICALS (NOT 'APIMEDS KOREA') NAMES YOUNGJIK CHO AS BOARD CHAIRMAN - SEC FILING
- New Appointment: Young Jik Cho has been appointed as the Chairman of the Board for a pharmaceutical company.
- Correction Notice: The announcement clarifies that the company is not related to "APIMEDS KOREA."
APIMEDS KOREA NAMES MR. CHO AS BOARD CHAIRMAN IN SEC FILING
- Appointment Announcement: Mr. Cho has been appointed as the Chairman of the Board for SEC Filings in South Korea.
- Significance of the Role: The position is crucial for overseeing regulatory compliance and corporate governance in the financial sector.
- Background of Mr. Cho: Mr. Cho brings extensive experience in finance and corporate management to his new role.
- Future Implications: His leadership is expected to influence the direction of SEC filings and enhance transparency in the market.
APIMEDS PHARMACEUTICALS REMOVES ELONA KOGAN, JAKAP KOO, CAROL O'DONNELL, AND BENNETT WEINTRAUB FROM BOARD OF DIRECTORS EFFECTIVE IMMEDIATELY, ACCORDING TO SEC FILING DATED MARCH 20
Company Changes: A pharmaceutical company has removed several directors from their positions, including Elona Kogan, Carol O'Donnell, and Bennett Weintraub.
Immediate Effect: The changes in the board of directors are effective immediately, indicating a swift transition in leadership.
Context of Changes: The removal of these directors may suggest a strategic shift or response to internal or external pressures within the company.
Future Implications: The impact of these changes on the company's operations and direction remains to be seen, as new leadership may bring different priorities and strategies.
Inscobee Rejects Allegations from MindWave Innovations, Inc.
- Board Restructuring: On March 20, 2026, Inscobee and Apimeds Korea executed a written consent to remove four directors and appoint three new ones, effective immediately, demonstrating strong shareholder intervention and intent to restructure corporate governance.
- Executive Changes: The new board decided to remove the CEO and CFO, appointing Mr. Cho as the new CEO, aiming to drive strategic transformation and enhance operational efficiency under new leadership.
- Escalating Legal Dispute: MindWave issued a statement without authorization from the new board, alleging breaches of the support agreement by Inscobee and Apimeds Korea, potentially leading to litigation and increasing legal risks and uncertainties for the company.
- Asset Ownership Controversy: Inscobee and Apimeds Korea raised concerns over MindWave's ownership of digital assets, specifically 1000 bitcoins, indicating information asymmetry during the merger process that could affect future business integration and strategic decisions.
APIMEDS Pharmaceuticals US Inc. Names Youngjik Cho as CEO and Junyoung Yu as Secretary, Effective Immediately - SEC Filing
Leadership Changes: Young Jik Cho has been appointed as the new CEO of Pharmaceuticals, while Jun Young Yu has taken on the role of Secretary effective immediately.
Strategic Focus: The leadership transition aims to enhance the company's strategic direction and operational efficiency in the pharmaceutical sector.
APIMEDS Pharmaceuticals US Inc. Terminates Dr. Vin Menon as CEO, Effective Immediately - SEC Filing
Pharmaceutical Developments: Recent advancements in pharmaceuticals have led to significant changes in treatment protocols.
Immediate Effects: The introduction of new medications has shown immediate positive effects on patient outcomes.
Dr. Vin Menon: Dr. Vin Menon has been a key figure in these developments, contributing to the field with innovative approaches.
Regulatory Changes: The regulatory environment is adapting to accommodate these new treatments, ensuring they are safe and effective for public use.
APIMEDS PHARMACEUTICALS (NOT 'APIMEDS KOREA') NAMES YOUNGJIK CHO AS BOARD CHAIRMAN - SEC FILING
- New Appointment: Young Jik Cho has been appointed as the Chairman of the Board for a pharmaceutical company.
- Correction Notice: The announcement clarifies that the company is not related to "APIMEDS KOREA."
APIMEDS KOREA NAMES MR. CHO AS BOARD CHAIRMAN IN SEC FILING
- Appointment Announcement: Mr. Cho has been appointed as the Chairman of the Board for SEC Filings in South Korea.
- Significance of the Role: The position is crucial for overseeing regulatory compliance and corporate governance in the financial sector.
- Background of Mr. Cho: Mr. Cho brings extensive experience in finance and corporate management to his new role.
- Future Implications: His leadership is expected to influence the direction of SEC filings and enhance transparency in the market.
APIMEDS PHARMACEUTICALS REMOVES ELONA KOGAN, JAKAP KOO, CAROL O'DONNELL, AND BENNETT WEINTRAUB FROM BOARD OF DIRECTORS EFFECTIVE IMMEDIATELY, ACCORDING TO SEC FILING DATED MARCH 20
Company Changes: A pharmaceutical company has removed several directors from their positions, including Elona Kogan, Carol O'Donnell, and Bennett Weintraub.
Immediate Effect: The changes in the board of directors are effective immediately, indicating a swift transition in leadership.
Context of Changes: The removal of these directors may suggest a strategic shift or response to internal or external pressures within the company.
Future Implications: The impact of these changes on the company's operations and direction remains to be seen, as new leadership may bring different priorities and strategies.
